Dana-Farber-Cancer Institute Inc.

New York University

The University of North Carolina at Chapel Hill

The University of Texas System

The General Hospital Corporation

The Brigham and Women's Hospital, Inc.

Children's Medical Center Corporation

G1 Therapeutics, Inc.

Acetylon Pharmaceuticals, Inc.

Kwok-kin Wong

Nathanael Schiander Gray

Pasi Antero Janne

James Elliott Bradner

Hwan Geun Choi

Jaebong Jang

Michael Eck

Peter Hammerman

Norman E Sharpless

Jay Copeland Strum

Jun Qi

Glenn Dranoff

Patrick Joseph Roberts

John Emerson Bisi

Margaret A Shipp

Michael Robert McKeown

Ronald A DePinho

Steven N Quayle

Bruce E Johnson

Lynda Chin

Giovanni Tonon

David Barbie

Jessie M English

Russell W Jenkins

Amir Aref

Nabeel Bardeesy

Carla F Kim

Yan Liu

Andrew Mark Scott

Diego H Castrillon

Thanh Barbie

Benjamin D Humphreys

Bjoern Chapuy

Zhao Chen

Christine F Brainson

Mark Bittinger

Chunxiao Xu

Dennis O Adeegbe

Sima Zacharek

Hua Zhang

Yuanwang Pan

Han Han

David Peng

Jiehui Deng

Derek P DiRocco

Hongbin Ji

Provided is a method for treatment of lung squamous cell carcinoma (LUSC) by administering to an individual in need of treatment one or more inhibitors of the RTK-Ras signaling pathway. The LUSC cells may carry a mutation in a KMT2D gene. The inhibitors of the RTK-Ras signaling pathway are SHP2 inhibitors or epidermal growth factor receptor (EGFR) inhibitors. Combinations of the SHP2 inhibitors and EGFR inhibitors can be used.

Therapeutic targeting ofmutant lung squamous cell carcinoma through RTK-RAS signaling inhibition

Provided are methods of sensitizing LKB1/STK11 deficient cancers to immune therapy. A method for treatment for LKB1/STK11 deficient cancers is provided comprising administration of inhibitor or inhibitors of one or more of NAMPT, CD38, SHP2, CXCR1/2, HDAC4 and PARP in combination with immunotherapy.

Combination therapy for treatment of LKB1 deficient cancers

The present invention provides methods of treating cancer by combination therapy with CDK4/6 inhibitors and immune checkpoint inhibition.

Compositions and methods of modulating anti-tumor immunity

The present invention is based on the identification of novel biomarkers predictive of responsiveness to anti-immune checkpoint inhibitor therapies.

Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response

The present invention provides methods for treating cancer using combinations of bromodomain and extra-terminal (BET) protein inhibitors and certain chemotherapeutic drugs.

Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors

The disclosure relates to pharmaceutical combinations comprising an HDAC6 selective inhibitor and a BET inhibitor for the treatment of cancer in a subject in need thereof. Also provided herein are methods for treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of an HDAC6 selective inhibitor and a BET inhibitor.

Methods of use and pharmaceutical combinations of HDAC inhibitors with BET inhibitors

The present disclosure provides compounds of any one of Formulae (I) and (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1 and/or EZH2 inhibitors. 

EZH2 inhibitors and uses thereof

The present invention provides methods of detecting cancer using biomarkers.

Methods of diagnosing and prognosing lung cancer

The present invention is based, in part, on the identification, of novel mitochondrial iron-sulfur (Fe&#x2014;S) cluster biosynthesis pathway biomarkers and modulators, and methods of use thereof, for identifying, assessing, preventing, and treating cancer.

Compositions and methods for identification, assessment, prevention, and treatment of cancer using NFS1 biomarkers and modulators

The disclosure relates to a compound having Formula (I'): and 

Inhibitors of EGFR and methods of use thereof

The present disclosure provides combination therapy of a transcription inhibitor and a kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may be useful in treating and/or preventing in a subject a proliferative disease, such as proliferative a disease that is resistant to the transcription inhibitor alone or the kinase inhibitor alone. In certain embodiments, the proliferative disease is a cancer. The combination of the transcription inhibitor and the kinase inhibitor is expected to be synergistic.

Combination therapy of transcription inhibitors and kinase inhibitors

The present invention provides methods of treating cancer, particularly cancers that had developed resistance to PD-1 and PDL-1 blockade. Also included are methods of identifying therapeutic targets for the treatment of cancer.

Methods for treating cancer

Provided herein are methods for culturing patient-derived tumor cell spheroids in a three-dimensional microfluidic device. The method comprises mincing primary tumor sample in a medium supplemented with serum; treating the minced primary tumor sample with a composition comprising an enzyme; collecting tumor spheroids having a diameter of 10 &#x3bc;m to 500 &#x3bc;m from the enzyme treated sample; suspending the tumor spheroids in biocompatible gel; and culturing the tumor spheroids in a three dimensional microfluidic device. Methods for identifying an agent for treating cancer and microfluidic devices that allow for the simultaneous exposure of the cultured patient-derived primary tumor cell spheroids to a treatment of choice and to control treatment are also provided.

Microfluidic cell culture of patient-derived tumor cell spheroids

The disclosure relates to a compound having Formula (I'): andin particular, Compound I-126: which modulates the activity of EGFR, a pharmaceutical composition comprising the compound, and a method of treating or preventing a disease in which EGFR plays a role.

The presently disclosed subject matter relates to methods and compositions for protecting cells and or tissues from damage due to ischemia. In particular, the presently disclosed subject matter relates to the protective action of cyclin dependent kinase 4/6 (CDK4/6) inhibitors administered to subjects that have been exposed to, or that are at risk of, ischemia.

Protection of renal tissues from ischemia through inhibition of the proliferative kinases CDK4 and CDK6

Growing community of inventors

Arlington, MA, United States of America

Kwok-kin Wong